RT Journal Article
SR Electronic
A1 Hitt Nichols, Emma
T1 ASCT for Multiple Myeloma: The Role of the Novel Agents
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 31
OP 33
DO 10.1177/1559897715570841
UL http://mdc.sagepub.com/content/14/55/31.abstract
AB With the advent of novel therapies, the mean survival rate of patients with multiple myeloma is now about 10 years. Prior to the approval of the novel therapies, stem cell transplantation was considered the first-line therapy for younger patients with multiple myeloma. Current prospective trials should shed light on delaying stem cell transplantation in favor of first-line treatment, so as to avoid both acute and long term toxicities in the years to come.